Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people in the community. However, results of current pharmacological treatment on functional dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators test whether rifaximin is also effective in curing post-prandial distress symptoms related to dyspepsia.
The aim of this study is to test the effects of rifaximin, a minimally absorbed antibiotics, on symptoms of patients with functional dyspepsia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
95
Queen Mary Hospital
Hong Kong, China
Adequate relief of dyspeptic symptoms at end of treatment
global symptom improvement
Time frame: end of treatment (week 2)
Individual dyspeptic symptom scores
Hong Kong Dyspeptic Index
Time frame: week 2, 4 and 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.